R. Agami
Division of Gene Regulation, the Netherlands
Cancer Institute, Amsterdam, The Netherlands
M. Aglietta
Department of Clinical Oncology, Institute for
Cancer Research and Treatment, University of
Turin, Candiolo, Italy
M. Andreeff
Section of Molecular Hematology and Therapy,
Department of Stem Cell Transplantation and
Cellular Therapy, The University of Texas MD
Anderson Cancer Center, Houston, Texas, USA
F. Bussolino
Department of Oncological Sciences, Institute
for Cancer Research and Treatment, University
of Turin, Candiolo, Italy
F. Ciardiello
Division of Medical Oncology, Department of
Experimental and Clinical Medicine and Surgery,
Second University of Naples, Italy
R.B. Clarke
School of Cancer and Enabling Sciences, Paterson
Institute for Cancer Research, University of
Manchester, UK
M.P. Colombo
Molecular Immunology Unit, Department of
Experimental Oncology and Molecular Medicine,
Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy
C.M. Croce
Department of Molecular Virology, Immunology
and Medical Genetics, Ohio State University
Medical Center and Comprehensive Cancer
Center, Columbus, Ohio, USA
E. Dejana
IFOM Foundation, IFOM-IEO Campus, University
of Milan, Milan, Italy
R. De Maria
Department of Hematology, Oncology and
Molecular Medicine, Istituto Superiore di Sanità ,
Rome, Italy
P.P. Di Fiore
IFOM Foundation, Department of Experimental
Oncology, European Institute of Oncology, IFOM-IEO
Campus, University of Milan, Milan, Italy
F. Di Nicolantonio
Laboratory of Molecular Genetics, Institute for
Cancer Research and Treatment, University of
Turin, Candiolo, Italy
J.D. Gallo
Early Development Group, Oncology Business Unit, Pfizer Italia, Milan, Italy
A. Gulino
Laboratory of Molecular Oncology, Department
of Experimental Medicine, Sapienza University
of Rome, Italy
G. Kroemer
INSERM, Institut Gustave Roussy, Villejuif, France
G. Melino
Biochemistry Laboratory, IDI-IRCCS, Department
of Experimental Medicine and Biochemical
Sciences, Tor Vergata University of Rome, Italy
P.G. Pelicci
Department of Experimental Oncology, European
Institute of Oncology, IFOM-IEO Campus, Milan,
Italy
M. Peters
Novartis Pharma, Basel, Switzerland
G. Piaggio
Molecular Oncogenesis Laboratory, Department
of Experimental Oncology, Regina Elena National
Cancer Institute, Rome, Italy
S. Piccolo
Department of Medical Biotechnologies, University
of Padua, Italy
M.A. Pierotti
Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy
Y. Rukazenkov
AstraZeneca Global R&D, Macclesfield, UK
S. Scherer
Global BioMarker, Roche/Genentech Inc, San
Francisco, California, USA
H.G. Stunnenberg
Radboud University Nijmegen, Nijmegen Center
for Molecular Life Sciences, Department of Molecular
Biology, Nijmegen, The Netherlands
D.A. Tuveson
Cambridge Research Institute, Cancer Research
UK, Cambridge, UK
A. Vacca
Department of Internal Medicine and Clinical
Oncology, University of Bari, Italy
K. Vousden
The Beatson Institute for Cancer Research, Glasgow,
Scotland, UK
N. Zaffaroni
Molecular Pharmacology Unit, Department of
Experimental Oncology and Molecular Medicine,
Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy
|